Pilot crash crushes little Galectin’s share price after NASH study fails
The next time a biotech team decides to run a quick proof-of-concept study to back up their clinical quest on a drug designed to fight a big-market disease, they might want to carefully consider what can go wrong.
Take Galectin $GALT, for example.
Developing a new NASH contender, a hot field for drug developers these days, the small Norcross, GA-based biotech decided to recruit 30 patients for a short “pilot” trial to run a few months, with a biomarker on liver fibrosis in focus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.